Eli Lilly's agreement to acquire AtaiBeckley for up to ~$3.8bn is the clearest signal yet that rapid-acting neuroplastogens have crossed from speculative science into serious pharmaceutical strategy. This is not the first time a major pharmaceutical company has moved on the field: Otsuka took Mindset Pharma private as early as 2023, but it is the largest such move to date. The deal rests on two clinical-stage assets, and both are worth understanding on their own terms. 

BPL-003 is a synthetic, proprietary intranasal formulation of mebufotenin benzoate, 5-MeO-DMT, being developed for treatment-resistant depression. Pharmacologically it is a serotonin receptor agonist with a notably short duration of action and uniquely ineffable acute subjective effects: intranasal delivery produces rapid absorption and elimination, which is precisely what allows a single dose to be given and the patient assessed for discharge inside roughly a two-hour clinic visit. It holds FDA Breakthrough Therapy Designation and has moved into Phase 3. 

VLS-01 is a buccal-film formulation of DMT, allowing for transmucosal delivery, in Phase 2b for treatment-resistant depression. It pursues the same underlying hypothesis through a different molecule and route: DMT is also a short-acting serotonin receptor agonist known for inducing intensely visual acute subjective effects.  

The rationale for treatment of TRD is based primarily on these compounds’ ability to induce greater neuroplasticity, and that a short, supervised psychedelic exposure can restore the brain's capacity to form and strengthen connections in mood-regulating networks at a cognitive level, a mechanism distinct from the slow and gradual neurotransmitter-level adjustment of conventional antidepressants. 

We ran UK site trials for both compounds at Clerkenwell Health — Beckley's BPL-003 programme and Atai's VLS-01 programme. Delivering these protocols to standard is demanding in ways conventional CNS and psychiatry studies are not, from dosing-day monitoring to rater training, and building sites capable of doing so consistently is what specialist infrastructure is for. 

What unites both programmes is the design constraint that makes them clinically deliverable: durable and significant effect from a single dose delivered within a short in-clinic session. An intervention that works but requires all-day monitoring does not scale; one that fits inside two hours can be integrated into existing psychiatric care. That is a large part of the significance of the pharmacology and formulation — and, plausibly, of what Lilly is acquiring. 

But a molecule is not a medicine until it can be delivered safely and reliably to real patients, and with compounds of this class that is the hard part, not an afterthought. The dosing environment, the monitoring, the trained healthcare practitioners in the room - this is the infrastructure that turns a promising signal into an approved therapy patients can access. A great deal of that practical work still lies ahead. This is the beginning of translating the science into clinical practice, not the end of it, and building the sites capable of delivering it to standard is precisely what specialist research infrastructure exists to do. We intend to be a central part of that work for a long time to come. 

This field has too often been argued as ideology. The more useful frame is the one this transaction implies: rigorous evidence, and therapies designed from the outset to be delivered and scaled. On both counts, congratulations to the team at ataiBeckley.